Company intelligence / Profile preview

Jecure Therapeutics

San Diego, California, United Statesjecuretx.com ↗

Ownership: Private
Development stage: Other

Overview

Jecure Therapeutics was a biotechnology company focused on the discovery and development of novel small molecule inhibitors of the NLRP3 inflammasome. The company's primary research programs targeted serious inflammatory conditions, with a specific emphasis on non-alcoholic steatohepatitis (NASH) and liver fibrosis. Founded in 2017 by Versant Ventures, Jecure leveraged proprietary structural biology insights to create a portfolio of highly selective NLRP3 antagonists. In November 2018, the company was acquired by Genentech to strengthen its pipeline in inflammatory and autoimmune diseases.

Therapeutic areas: ImmunologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Jecure Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jecure Therapeutics.